Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 6, 2003, Pages 751-764

  Gisbert, J P ^a,c   Khorrami, S ^a   Calvet, X ^b   Pajares, J M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL DE SABADELL   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 0037444889     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01450.x     Document Type: Review

References (74)

1. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-7.
2. Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 725-42.
3. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 3-10.
4. Stedman CA. Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
5. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001; 61: 2327-56.
6. Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis 2001; 19: 134-43.
7. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
8. Hirai M, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995; 30: 461-4.
9. Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 458-61.
10. Fujioka T, Kawasaki H, Su WW, Nasu M. In vitro antimicrobial activity against H. pylori and clinical efficacy of various drugs. Nippon Rinsho 1993; 51: 3255-60.
11. Fujiyama K, Fujioka T, Kodama R, Nasu M. Effect of E3810, a novel proton pump inhibitor, against Helicobacter pylori [abstract]. Am J Gastroenterol 1994; 89: 1371.
12. Tsutsui N, Taneike I, Ohara T, et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 3069-73.
13. Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter 2001; 6: 125-9.
14. Lopez-Brea M, Domingo D, Martinez M, Escudero E, Jimenez S, Alarcon T. In vitro activity of rabeprazole compared with omeprazole in Helicobacter pylori clinical isolates [abstract]. Gut 2001; 49(Suppl. II): A7(Abstract).
15. Barth J, Hahne W. Review article: rabeprazole-based therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 31-3.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
17. Di Caro S, Zocco MA, Cremonini F, et al. Efficacy of 5, 7 and 10 days levofloxacin-based dual therapy for H. pylori eradication. Gut 2001; 49(Suppl. II): A90(Abstract).
18. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998; 93: 1909-13.
19. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341-8.
20. Miyoshi M, Mizuno M, Ishiki K, et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-8.
21. Kawai T, Ogua K, Kudou T, et al. Comparison of dual therapy of rabeprazole plus amoxicillin and triple therapy for cure of Helicobacter pylori infection [abstract]. Gastroenterology 2001; 120(Suppl. 1): 2971.
22. Humphries TJ, Bassion S. Pilot studies on the effects of rabeprazole sodium (E3810), amoxicillin, and placebo on the eradication of H. pylori [abstract]. Am J Gastroenterol 1996; 91: 1914.
23. Uchihara M, Izumi N, Noguchi O, et al. Cytochrome P450 2C19 (CYP2C19) genotype status is not associated with cure rates of dual therapy with rabeprazole and amoxicillin for Helicobacter pylori [abstract]. Gastroenterology 2001; 120(Suppl. 1): 2985.
24. Wong BC, Wong WM, Yee YK, et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1959-65.
25. Vakil NHJS, Lanza FL, Nardi L, Hahne W, Barth J. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA [abstract]. Gastroenterology 2002; 122: 551.
26. Hwang-Huei W, Kuan-Fu L, Zong-Yee L. A study on the efficacy of three-day versus seven-day rabeprazole-based triple therapy in the eradication of Helicobacter pylori in peptic ulcers [abstract]. Gut 2002; 51(Suppl. 2): A61(Abstract).
27. Luth S, Teyssen S, Kolbel CB, Singer MV. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease - a pilot study. Z Gastroenterol 2001; 39: 279-81, 284-5.
28. Gambaro C, Bilardi C, Iiritano E, et al. 4-day vs 7-day triple therapy with rabeprazole, clarithromycin and metronidazole for H. pylori eradication [abstract]. Gastroenterology 2002; 122: W1199.
29. Isomoto H, Furusu H, Morikawa T, et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1619-23.
30. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000; 5: 88-93.
31. Kawamura N, Sugiyama T, Saito M. et al. Eradication efficacy of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori does not depend on P450 genotype of the patients [abstract]. Gut 2000; 47(Suppl. I): A105(Abstract).
32. Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 1479-84.
33. Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1083-7.
34. Kuwayama H, Takahashi M, Takada H, Luk G. Comparison of standard dose rabeprazole and double dose omeprazole in PPI-based triple therapy for Helicobacter pylori infection - a randomized clinical trial [abstract]. Gastroenterology 2001; 120(Suppl. 1): 2970.
35. Inaba T, Mizuno M, Kawai K. et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002; 17: 748-53.
36. Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000; 45: 77-82.
37. Hizawa K, Nakahara T, Yano Y, Inuzuka S, Akagi K, Matsumoto T. Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection. J Clin Gastroenterol 2000; 31: 338-9.
38. Kawabata HK, Hayakumo T, Nakajima M, et al. Effects of different PPIs, genetic difference in CYP2C19 status and antibiotic susceptibility patterns on the cure rate of H. pylori infection by one-week triple therapy: results of a randomized trial in Japan [abstract]. Gastroenterology 2001; 120(Suppl. 1): 2964.
39. Murakami K, Nasu M, Fujioka T, et al. Evaluation of the eradication effect of Helicobacter pylori against clarithromycin-sensitive strains and clarithromycin-resistant strains in triple therapy with rabeprazole, amoxicillin, and clarithromycin: randomized comparison with triple therapy using lansoprazole [abstract]. Gut 2002; 51(Suppl. 2): A99 (Abstract).
40. Miki I, Aoyama N, Sakai T, et al. The key to successful eradication of H. pylori, using lansoprazole or rabeprazole based triple therapy, is clarithromycin resistance, not CYP2C19 polymorphism [abstract]. Gastroenterology 2001; 120(Suppl. 1): 2984.
41. Danese S, Armuzzi A, Romano A, et al. Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication. Hepatogastroenterology 2001; 48: 465-7.
42. Suga M, Takada H, Kanozawa S, Koizumi K, Takahashi M, Kiwayama H. Metronidazole (MNZ) is more effective than amoxicillin (AMOX) in combination with clarithromycin (CAM) and proton pump inhibitor (PPI) for Helicobacter pylori (H. pylori) eradication in Japan [abstract]. Gastroenterology 2002; 122: W1211.
43. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6.
44. 13C urea breath test for predicting resistance to therapy in Helicobacter pylori infection. Gut 2000; 47(Suppl. I): A116(Abstract).
45. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14: 1625-9.
46. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 417-21.
47. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001; 33: 671-5.
48. Zullo A, Vaira D, Vakil N, et al. A successful first-line regimen for Helicobacter pylori (HP) eradication: a multicenter study [abstract]. Gut 2002; 51(Suppl. 2): A91(Abstract).
49. Maev I, Yushchouk N. Efficacy of Helicobacter pylori eradication regimens in functional dyspepsia and peptic ulcer [abstract]. Gut 2001; 49(Suppl. II): A63(Abstract).
50. Takahashi M, Takada H, Kuwayama H. Serum total cholesterol concentration is increased after successful Helicobacter pylori eradication therapy [abstract]. Gastroenterology 2002; 122: T1508.
51. Karatapanis S, Georgopoulos S, Papakonstantinou L, Papamarkos D, Mentis A, Artikis V. Rabeprazole 7-days vs rabeprazole 10-days triple therapy in the eradication of H. pylori infection - a randomized study [abstract]. Gut 2000; 47(Suppl. I): A107(Abstract).
52. Cavestro GM, Dal Bo N, Franceschi M, et al. Comparison of different dosages of PPI in one-week Helicobacter pylori eradication therapy [abstract]. Gut 2001; 49(Suppl. II): A92(Abstract).
53. Pilotto A, Di Mario F, Franceschi F, et al. Efficacy of one-week triple therapies with low-dose rabeprazole and clarithromycin plus standard-dose amoxicillin or tinidazole for the cure of H. pylori infection in elderly patients [abstract]. Gut 2001; 49(Suppl. II): A95(Abstract).
54. Takano R, Takahashi M, Hirakawa J, Takada H, Kuwayama H. Metronidazole and clarithromycin resistant Helicobacter pylori after triple agent eradication therapy including both these antibiotics [abstract]. Gastroenterology 2001; 120 (Suppl. 1): 3008.
55. Takahashi M, Takada H, Mori Y, Kuwayama H. Pepsinogen 1 : 2 ratio as a predictor for development of esophagitis after Helicobacter pylori eradication therapy [abstract]. Gastroenterology 2002; 122: W1172.
56. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
57. Cammarota G, Cianci R, Vero V, Urgesi R, Gasbarrini C. Efficacy of rabeprazole/levofloxacin-based triple therapy for Helicobacter pylori eradication [abstract]. Gut 2002; 51(Suppl. II): A95(Abstract).
58. Hawkey CJ, Atherton JC, Treichel HC, Krankenhjaus J, Ravic M, Thjodleifsson B. Rabeprazole vs omeprazole in 7-day, triple-therapy H. pylori eradication regimens for peptic ulcer [abstract]. Gastroenterology 2001; 120(Suppl. 1): 2950.
59. Ohning GV, Barbuti RC, Kovacs TO, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 701-8.
60. Bosques-Padilla FJ, Tijerina-Menchaca R, Maldonado-Garza HJ, Garza-Gonzalez E. Bacteriostatic and bactericidal activity of rabeprazole in Helicobacter pylori clinical isolates [abstract]. Gut 2002; 51(Suppl. II): A100(Abstract).
61. Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995; 18: 1053-6.
62. Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996; 19: 182-7.
63. Cloud ML, Enas N, Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 1998; 43: 993-1000.
64. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997; 113: S131-48.
65. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-29.
66. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-37.
67. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-64.
68. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
69. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-9.
70. Yamagata S, Ishimori A, Sato H, Ishihara K, Masuda M. Secretory function of the stomach of Japanese with endoscopically normal gastric mucosa. Gastroenterol Jpn 1975; 10: 162-7.
71. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-30.
72. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-54.
73. VandenBranden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6: 81-91.
74. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 27-36.